Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-01 12:11:45 - browse：431

Layoff concept illustration of empty desks and people walking away. — Adobe

Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biology called biomolecular condensates, laid off 15% of its staff on Tuesday and acknowledged that a pair of collaboration deals with pharma companies had fallen apart.

The downsizing is temporary, CEO Ameet Nathwani told STAT. The company needed to hire new employees with expertise to help move the company’s first drugs into clinical trials and expand its AI capabilities. And with funding for early-stage biotechs still sparse, leadership opted to cut some positions and use the savings to fill new ones over the coming months. Roughly 20 positions were cut.

“We talked to investors right now [about raising more money], and they think that the environment for a preclinical company — it’s not even worth having that discussion,” Nathwani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： New study raises questions about niacin and heart health

WSS

FDA warns medical device makers about rise in fabricated data

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Designating disabled people as health disparity population is crucial

As AI regulations shape up, health tech startups beg for clarity

Doulas covered by Medicaid under New York's new plan

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

knowledge

Wikipedia

leisure time

Sports medicine is finally prioritizing gender equality

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

As demand for Covid shots wanes, Moderna seeks its next success

Abridge raises $150m as clinical notes automation market heats up

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The nurse manager staffing crisis is hurting patients

Hollywood unions extend contract negotiations for actors

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Malaria cases in Florida and Texas: Here’s what you need to know

New study raises questions about niacin and heart health

explore

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Secretariat’s lessons for human medicine

In 'major milestone,' FDA approves first cell therapy for solid tumors

As AI regulations shape up, health tech startups beg for clarity

How I ended up pumping milk in a bathroom stall at JPM 2024

Ukraine seeks to reclaim its role as a hub for clinical trials

entertainment

Wikipedia

focus

leisure time